Sutacimig Cuts Prothrombin Time Over 50% After Single Dose in Two Patients
COAG sits 87% above its 52-week low of $23.
Summary
Two patients with severe congenital Factor VII deficiency received a single sutacimig dose and both saw prothrombin time shorten by more than 50%. One participant with available data showed roughly 5x accumulation of endogenous FVII(a) through Day 22, which points to sustained target engagement. The readout is thin — two patients for the PT effect and exposure data from just one — so it is early proof of mechanism rather than proof of benefit. Separately, HMB-003 cut severe bleeding days in a monkey model, a preclinical result that does not establish human efficacy. This follows the August 10-Q, where the FDA endorsed a Phase 3 trial for sutacimig and $457.5M in cash funds operations into 2029. HMB-003 Phase 1 human data are expected mid-2027 and are the next real test.
At the time of this announcement, COAG was trading at $43.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $23.00 to $55.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.